Chukwunonso Nwabufo is the founder of OneDrug and a multiple award-winning pharmacologist with over six years’ experience in drug development across academia and the pharmaceutical industry. Nwabufo contributed to the development of Remdesivir and Lenacapavir approved for the treatment of COVID-19 and HIV respectively during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease.
Nwabufo has received more than 20 awards and recognitions worth more than C$200K in funding due to academic, research, and leadership accomplishments. Nwabufo is the author of 15 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs.
Currently, Nwabufo is a PhD candidate in pharmaceutical sciences at the Leslie Dan Faculty of Pharmacy at the University of Toronto and has received the prestigious Canadian Institutes of Health Research Canada Graduate Scholarship Doctoral Award, and Canadian Institutes of Health Research Canada Graduate Scholarships – Michael Smith Foreign Study Supplements Award to support his research which is investigating pharmacological strategies for improving the clinical efficacy and safety of respiratory medicines, particularly, promising drugs for treating SARS-CoV-2 infection. His research work on optimizing the pharmacology of respiratory medicines has received C$121K in funding from the Leslie Dan Faculty of Pharmacy.
Nwabufo serves as an editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He is an abstract screener for PharmSci360 conference and vice-chair for the Pharmacokinetic, Pharmacodynamic and Drug Metabolism Community of the American Association of Pharmaceutical Scientists, USA.